GlassScriptPhysician profile
Alka Srivastava
NPI 1780782185
$3,783.10
in general payments reported to CMS, 2019-2025
40 companies · $664 in 2025
The $664 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $289 · 2021: $178 · 2022: $822 · 2023: $732 · 2024: $808 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.37 |
| Education | $329.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $328.02 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Astellas Pharma US INC | $312.07 | 2019-2025 | Xtandi, Padcev |
| Celgene Corporation | $269.28 | 2022-2025 | Reblozyl, Abecma, Pomalyst |
| Amgen INC. | $241.42 | 2020-2023 | Kyprolis, Lumakras |
| Daiichi Sankyo INC. | $225.96 | 2024-2025 | Enhertu, Datroway |
| Emd Serono, INC. | $216.62 | 2022-2025 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $191.70 | 2020-2025 | Reblozyl, Opdivo |
| Pfizer INC. | $191.14 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $188.92 | 2022-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $150.78 | 2020-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $150.73 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $149.46 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Glaxosmithkline, LLC. | $108.19 | 2022-2025 | Jemperli, Zejula |
| Eisai INC. | $91.43 | 2022-2024 | |
| Clovis Oncology, INC. | $77.90 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Srivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.